Allergan Plc (AGN)

166.47
NYSE : Health Technology
Prev Close 165.73
Day Low/High 165.42 / 167.29
52 Wk Low/High 114.27 / 197.00
Avg Volume 4.73M
Exchange NYSE
Shares Outstanding 328.10M
Market Cap 54.38B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.77%)
Allergan To Report Second Quarter 2019 Financial Results

Allergan To Report Second Quarter 2019 Financial Results

DUBLIN, Aug. 2, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release second quarter 2019 financial results on Tuesday, August 6, 2019, prior to the open of U.

Trump Just Deepened the Tariff War -- Retail Investors Were the Smart Ones

Trump Just Deepened the Tariff War -- Retail Investors Were the Smart Ones

Retail investors are sitting pretty after Trump enacted more tariffs. See their fancy footwork executed in July.

Powell's Verbal Fouls, an Equity Beatdown and Silence of the Lam: Market Recon

Powell's Verbal Fouls, an Equity Beatdown and Silence of the Lam: Market Recon

The Fed chairman's news conference threw markets for a loop with hawkish words that did not support the Fed's dovish actions.

Ashley Tisdale Joins The Allergan 'Women Who Know' Campaign

Ashley Tisdale Joins The Allergan 'Women Who Know' Campaign

Actress encourages women to take active roles in their reproductive health, including researching birth control options

What to Watch for Earnings In the Second Half of 2019

What to Watch for Earnings In the Second Half of 2019

Edward Jones' Investment Strategist says Q3 and Q4 earnings season will be solid but not spectacular. Here's why.

Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants And Tissue Expanders

Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants And Tissue Expanders

-- Global Action Follows Notification of Updated Safety Information from the U.S.

Boeing, Tesla, Facebook, Snap, U.S.-China Trade Talks - 5 Things You Must Know

Boeing, Tesla, Facebook, Snap, U.S.-China Trade Talks - 5 Things You Must Know

U.S. stock futures are lower as U.S.-China trade talks are set to resume; the Department of Justice launches a new probe into whether Alphabet, Amazon, Facebook and Apple have been stifling competition; Tesla, Boeing, Ford, Facebook and Caterpillar report earnings.

Allergan Declares Third Quarter 2019 Cash Dividend Of $0.74 Per Ordinary Share

Allergan Declares Third Quarter 2019 Cash Dividend Of $0.74 Per Ordinary Share

- Dividend to be Paid on September 13, 2019 -

Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States

Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States

First Biosimilar Avastin® and Herceptin® Products to Launch in the United States

Hagens Berman: Federal Judge Greenlights Class-Action Antitrust Lawsuit Against Allergan Subsidiaries For Loestrin 24, Minastrin And Generics

Hagens Berman: Federal Judge Greenlights Class-Action Antitrust Lawsuit Against Allergan Subsidiaries For Loestrin 24, Minastrin And Generics

A federal judge yesterday greenlighted a class-action lawsuit against Allergan subsidiaries Warner Chilcott and Watson for overcharging direct purchasers for Loestrin 24, Minastrin and generic equivalents, according to Hagens Berman.

U.S. FDA Accepts Allergan's New Drug Application For Bimatoprost Sustained-Release In Patients With Open-Angle Glaucoma Or Ocular Hypertension

U.S. FDA Accepts Allergan's New Drug Application For Bimatoprost Sustained-Release In Patients With Open-Angle Glaucoma Or Ocular Hypertension

-- Filing included data from the Phase 3 ARTEMIS studies, which demonstrated that the majority of patients remained treatment free for at least 1 year following 3 treatments with Bimatoprost Sustained-Release --

Jim Cramer: Don't Play Earnings Season, Invest in It

Jim Cramer: Don't Play Earnings Season, Invest in It

Here are my five rules for handling earnings season.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGN, BPFH, TRTN Downgrades: HMG, PIH Initiations: DHXM Read on to get TheStreet Quant Ratings' detailed report:

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.

Planet Fitness, Allergan, Amarin: 'Mad Money' Lightning Round

Planet Fitness, Allergan, Amarin: 'Mad Money' Lightning Round

Jim Cramer weighs in on Planet Fitness, Allergan, Amarin, MPLX, Zynerba Pharmaceuticals, Schnieder National, United Parcel Service and more.

Allergan Continues To Demonstrate Leadership In Migraine With 29 Presentations At The 2019 American Headache Society Annual Meeting

Allergan Continues To Demonstrate Leadership In Migraine With 29 Presentations At The 2019 American Headache Society Annual Meeting

-- Allergan MIND™, Allergan's migraine franchise, showcases data highlighting BOTOX® (onabotulinumtoxinA) for Chronic Migraine, and two investigational products: ubrogepant and atogepant --

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie Rebounds as Market Warms to Allergan Deal, Botox Potential

AbbVie Rebounds as Market Warms to Allergan Deal, Botox Potential

AbbVie's deal for Allergan will give it a new revenue stream in Botox, helping offset potential lower revenue from arthritis drug Humira, which is losing patent protection.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Replay: What to Watch in The Markets: AbbVie-Allergan, Micron, Buffett, and More

Replay: What to Watch in The Markets: AbbVie-Allergan, Micron, Buffett, and More

The ActionAlertsPLUS team breaks down what investors need to know on Tueday, including: AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.

Getting Nervous

After days of complacency, we see a shift in sentiment and folks are getting the jitters.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Allergan Plc

SHAREHOLDER ALERT: WeissLaw LLP Investigates Allergan Plc

NEW YORK, June 25, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Allergan Plc ("Allergan" or the "Company") (NYSE: AGN) in connection with the proposed...

5 Blockbuster M&A Deals of 2019

5 Blockbuster M&A Deals of 2019

AbbVie takes over Allergan. But, it's not the biggest deal of 2019...

Dow Ends Lower, Stocks Fall as Powell Says Fed 'Grappling' with Rate Cut

Dow Ends Lower, Stocks Fall as Powell Says Fed 'Grappling' with Rate Cut

Major indexes declined Tuesday after Federal Reserve Chairman Jerome Powell hedged on a possible rate cut.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

AbbVie Buys Allergan for $63 Billion: Was the Price Just Right?

AbbVie Buys Allergan for $63 Billion: Was the Price Just Right?

AbbVie to purchase botox maker Allergan in $63 billion deal, but is the price just right?

Allergan Agrees to $63 Billion Takeover From AbbVie in Blockbuster Pharma Deal

Allergan Agrees to $63 Billion Takeover From AbbVie in Blockbuster Pharma Deal

Allergan shares surged the most in more than 25 years Tuesday after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie .

TheStreet Quant Rating: C (Hold)